Risperidone-induced priapism: a case report and literature review

Sarra Ateb, Taoufik Fourati, Hammadi Ben Rejeb, Dominique Januel and Noomane Bouaziz

Abstract: Priapism is a rare pathological condition defined as painful and persistent penile erection that is unrelated to sexual stimulation. It can be classified as ischaemic or non-ischaemic. Many causes have been attributed to ischaemic priapism, including the use of some medications such as antipsychotics. The mechanism of priapism associated with antipsychotics is thought to be related to alpha-adrenergic blockage that is mediated by the alpha receptors in the corpora cavernosa of the penis. In this paper, we describe a case of a patient who suffered from Risperidone-induced priapism, and how this adverse effect was resolved by switching to olanzapine followed by olanzapine pamoate. A literature search on PubMed/Medline up to 2011 was conducted by some doctors from London and found 30 cases of priapism associated with risperidone. Based on this work, we searched PubMed through 2021, using the keywords ‘priapism’ and ‘risperidone’ and found a total of 43 cases of priapism involving risperidone. Priapism is not correlated with the dosage of this psychotropic drug, and has also occasionally occurred when risperidone has been used in conjunction with another drug. The question of choosing a replacement antipsychotic after the first one has induced priapism, remains problematic. It would be preferable to switch to a drug with less marked alpha1-blocking properties, but no consensus has been reached as to the best choice of medication. Finally, any prescription of an antipsychotic treatment must be preceded by a careful interrogation in search of risk factors for priapism, and the patient should be made aware of the possible occurrence of this side effect and the need to then seek urgent medical advice.

Keywords: olanzapine pamoate monohydrate, priapism, risperidone, side effects

Received: 24 February 2022; revised manuscript accepted: 26 June 2022.
In this paper, we report a case of a patient who suffered from risperidone-induced priapism, and how this adverse effect was resolved. Written informed consent of the patient was taken before the case was submitted for publishing.

Case report

Mr. X was 22-year-old, single, unemployed, and living with his mother. The onset of his illness is believed to be in adolescence, but his first psychiatric hospitalization was in 2018, when he was diagnosed with schizophrenia. The patient was put on 150 mg of haloperidol decanoate every 28 days. Later that year, he was rehospitalized following a psychotic relapse caused by the discontinuation of his treatment, and he received the same antipsychotic.

In October 2019, he again stopped taking his medication and had a relapse that required hospitalization in a private hospital. During this relapse, the patient presented alarming symptoms, including heteroaggressive threats against his mother that were underpinned by a delusion of persecution. He also presented behavioral oddities (he tore his pajamas and tried to swallow pieces of them, and he presented an excoriation disorder brought on by delusions). He was put on risperidone (4 mg), diazepam (10 mg) and trihexyphenidyl (5 mg). Seven days after the start of this treatment, and upon developing priapism, the patient was referred to the emergency room of a hospital, where treatment could not be carried out due to the lack of an available urologist. After being transferred to the emergency room at another hospital, an intracavernous injection of Etilefrine (10 mg) was administered without success, and a cavernous puncture in the operating room was proposed but refused by the patient. After the spontaneous resolution of the priapism, an magnetic resonance imaging (MRI) of the corpora cavernosa was requested in order to evaluate the possible sequelae.

This MRI was performed 1 month after the priapism episode, and it did not detect any significant abnormality. During a follow-up urological consultation, a urologist explained to the patient the possibility of further erectile dysfunction despite the normal imaging. Immediately after this episode of priapism, the patient’s antipsychotics were stopped, and he was prescribed benzodiazepines only.

Given the persistence of the patient’s behavioral disorders, which were difficult to manage in a private hospital, the patient was involuntarily admitted to our psychiatric inpatient unit for further care. Due to the severity of the auto- and hetero-aggressive behaviors underpinned by delusions and bizarre behavior, the patient was given antipsychotics. Olanzapine was chosen, as it is theoretically one of the least likely drugs to cause priapism.3,5

The patient began his treatment on extremely low doses (2.5 mg/day), with a very careful increase (2.5 mg per day every 3 days) to reach an effective dose (20 mg/day). Diazepam was concurrently administered, for its sedative effect. This treatment program was well tolerated from a general and urological standpoint. After 1 month, the continued tolerance enabled a switch from oral treatment to an extended-release injection (300 mg). The patient tolerated these therapeutic changes without any sign of priapism.

In all, 20 mg of olanzapine, followed by 300 mg of olanzapine pamoate monohydrate every 28 days, then 405 mg of olanzapine pamoate monohydrate every 28 days, led to a significant improvement in symptoms, with the disappearance of hostile behavior, a reduction in the frequency and intensity of delusions, and the disappearance of bizarre behaviors, particularly excoriation disorder. This patient had had no history of priapism before the episode previously described. He had no risk factors for priapism other than taking antipsychotic medication. He had never had a hematological disorder, had never taken medication for erectile dysfunction, and had had no history of consuming illegal substances such as cocaine or cannabis. At the time of the priapism, he was not taking any medication other than diazepam, risperidone, and trihexyphenidyl. He was a nonsmoker, and had never had a pelvic or genital trauma. He reported no specific family history of priapism, and denied having any allergies to medication.

Regarding the imputability of priapism to risperidone in our patient, a score of 7 was found on Naranjo et al.’s8 Adverse-Reaction Probability Scale. The reaction was therefore considered ‘Probable’. During his outpatient follow-up, clinical improvement and good tolerance were confirmed. Currently, the patient regularly takes his long-acting olanzapine injections and reports satisfaction with this treatment.
Discussion

Priapism can be classified as ischaemic (low flow) or non-ischaemic (high flow). The non-ischaemic form is rare and usually follows trauma to the penis or perineum. The most common causes of low-flow priapism are sickle cell disease, spinal cord injury, substance use (including alcohol and cocaine), and medication. Psychotropic medications (including atypical and typical antipsychotics, anticonvulsants, and antidepressants) are the most common causes of drug-induced priapism.

The exact origin of antipsychotic-induced priapism remains unknown. Nevertheless, some etiopathogenic theories have been suggested. Among these is a neuromuscular hypothesis involving the antagonism of α-adrenergic receptors, which is the most widely accepted theory. Indeed, the contraction of smooth muscle cells of the resistance arteries and the trabecular system, mediated by noradrenaline, causes detumescence and penile flaccidity, and their relaxation leads to an increase in blood flow and erection.

Norepinephrine acts via the antagonism of α1 and, to a smaller degree, α2 adrenergic receptors. Blocking these receptors could therefore result in a prolonged erection and intracavernous blood stasis. This would cause hypoxia and acidosis that could lead to irreversible fibrosis. Usually, this vicious cycle can only be interrupted by surgical interventions, such as the aspiration of blood from the corpora cavernosa, an injection of phenylephrine, and the creation of a shunt.

Several drugs have been linked to priapism, including urology and cardiology medication such as prazosin, tamsulosin, doxazosin, nifedipine and labetalol. Priapism is also a documented side effect of trazadone, an antidepressant which can act as an α-adrenergic receptor antagonist. In addition, anticoagulant drugs, including warfarin and intravenous heparin, corticosteroids, and oral hypoglycemic drugs (e.g. tolbutamide), may increase the risk of priapism. Despite early reports, however, there has been little research into the frequency with which priapism occurs secondary to psychotropic medications. The available literature indicates that priapism has been attributed to the use of antipsychotics in around 15% to 26% of cases.

The affinity of antipsychotics to α-adrenergic receptors varies from one antipsychotic to another. Richelson studied a series of antipsychotics and established a specific affinity for each drug by determining the equilibrium dissociation constants (KD’s) of the α1-receptors. He took prazosin, the molecule with the highest α1-adrenergic affinity, estimated at 250 (10−7 × 1/KD) as a standard. This affinity was 38.5 for chlorpromazine, 37 for risperidone, but only 2.3 for olanzapine.

An American study conducted by Andersohn et al. which included 144 cases of antipsychotic-induced priapism, studied the relationship between the degree of affinity to the α-adrenergic receptors of antipsychotics and the occurrence of priapism by calculating the reporting odds ratios (RORs) for each drug, being 52.6 for chlorpromazine, 16.4 for risperidone, 10 for aripiprazole, and 1.5 for olanzapine. The question of choosing a replacement antipsychotic for one that induced a priapism, remains problematic, and few authors have focused on alternatives for these patients.

Another challenge for clinicians is how to manage priapism when a patient is in the midst of a psychotic relapse. First, non-recognition of priapism and its potentially serious consequences may cause a diagnostic and therapeutic delay. Second, the patient may not cooperate with the urology team, which would hinder the implementation of the proposed therapeutic measures. Indeed, our patient refused the cavernous puncture that the urologists recommended. However, the longer the duration of the priapism, the higher the risk of ischemia, acidosis and long-term fibrosis of penile tissues. Penile ischemia following priapism could eventually lead to penile amputation. Early management is essential to improve the outcome.

Risperidone, which caused the priapism in our patient, has been frequently associated with this adverse effect. Paklet et al. conducted a literature search on PubMed/Medline up to 2011, and found 30 cases of priapism associated with risperidone. Based on this work, we searched PubMed through 2021, without time or language restrictions, using the keywords ‘priapism’ and ‘risperidone’ and found 13 additional case reports of priapism involving risperidone (see Table 1).

Numerous case reports on risperidone-induced priapism have shown that this phenomenon can occur days or even years after starting this drug, even at low...
Table 1. Reports of antipsychotics induced priapism.

| Case report                  | Age     | Risperidone dose                              | Time to onset | Association with other treatment(s) | History of priapism with other molecules | Type and dose of antipsychotic after priapism |
|-----------------------------|---------|-----------------------------------------------|---------------|-------------------------------------|--------------------------------------------|---------------------------------------------|
| Makesar and Thome\(^{18}\) | 31 years | 1 single dose of 16 mg                        | 24 hours      | No                                  | No                                         | Unknown                                    |
| Koirala et al.\(^{19}\)     | Middle aged | Switch from oral to Risperdal Consta    | 1 week        | No                                  | No                                         | Unknown                                    |
| Koirala et al.\(^{19}\)     | 14 years | 1 mg/day                                      | Unknown       | No                                  | No                                         | Unknown                                    |
| Ankem et al.\(^{20}\)       | 47 years | 4 mg/day                                      | Unknown       | No                                  | No                                         | Unknown                                    |
| Maizel et al.\(^{21}\)      | 44 years | Unknown                                       | Unknown       | No                                  | No                                         | Unknown                                    |
| Nicolson and McCurley\(^{22}\) | 46 years | 8 mg/day                                      | Unknown       | Lorazepam                          | No                                         | Unknown                                    |
| du Toit et al.\(^{23}\)     | 44 years | 8 mg/day                                      | Unknown       | Trazodone                           | Quetiapine, Olanzapine                     | Unknown                                    |
| Slauson and LoVecchio\(^{24}\) | 28 years | Unknown                                       | 4 days        | Venlafaxine                         | No                                         | Unknown                                    |
| Haberfellner\(^{25}\)       | 22 years | 4 mg/day                                      | 4 weeks       | Sertraline                          | No                                         | Unknown                                    |
| Sharma and Fleisher\(^{14}\) | 31 years | 5 mg/day                                      | 8 years       | No                                  | Aripiprazole                               | Unknown                                    |
| Madhusoodanan et al.\(^{26}\) | 65 years | 1 mg/day                                      | 6 weeks       | No                                  | No                                         | Unknown                                    |
| Kirshner and Davis\(^{27}\) | 50 years | Risperdal Consta 25 mg/15 days + Oral 6 mg/day | 24 hours      | No                                  | Risperdal Consta 25 mg/15 days             | Unknown                                    |
| Emes and Millson\(^{28}\)   | 50 years | 10 mg/day                                     | 12 weeks      | Lithium + Lorazepam                | No                                         | Clozapine                                  |
| Sirota and Bogdanov\(^{29}\) | 19 years | 2 mg/day                                      | 5 days        | No                                  | No                                         | Olanzapine 10 mg/day                       |
| Bourgeois and Mundh\(^{13}\) | 26 years | 3 mg/day                                      | 1 year        | Divalproex sodium                   | No                                         | Olanzapine 10 mg/day                       |
| Relan et al.\(^{30}\)       | 32 years | 5 mg/day                                      | 2 weeks       | No                                  | No                                         | Flupenthixol 1 mg/day                      |
| Reeves and Mack\(^{31}\)    | 22 years | 4 mg/day                                      | 5 years       | Clonazepam + Vitamin E + Multivitamins | Ziprasidone                               | Olanzapine 10 mg then 25 mg/day            |
| Penaskovic et al.\(^{32}\)  | 21 years | Unknown                                       | Unknown       | No                                  | Olanzapine, Quetiapine                     | Olanzapine 15 mg/day                       |
| Yang and Tsai\(^{33}\)      | 13 years | 2 mg/day                                      | 2 months      | Paroxetine                          | No                                         | Unknown                                    |
| Dods et al.\(^{24}\)        | 49 years | Risperdal Consta dose                         | 1 month       | No                                  | No                                         | Oral fluphenazine                          |
| Lin et al.\(^{25}\)         | 26 years | 3 mg/day                                      | 3 years       | Ginkgo Biloba                       | No                                         | Risperidone 3 mg/day                       |
| Case report | Age   | Risperidone dose | Time to onset | Association with other treatment(s) | History of priapism with other molecules | Type and dose of antipsychotic after priapism |
|-------------|-------|------------------|---------------|-------------------------------------|------------------------------------------|---------------------------------------------|
| Freudenreich²⁶ | 29 years | 3 mg/day | 4 weeks | Citalopram | No | Haloperidol |
| Brichart et al.⁵ | 55 years | 2 mg/day | Few years | Unknown | No | Risperidone 2 mg/day |
| Brichart et al.⁵ | 26 years | 4 mg/day | Few years | Unknown | No | Unknown |
| Rosenberg et al.³⁷ | 49 years | 8 mg/day | 2 days | Lithium | Quetiapine, Trazodone | Aripiprazole 5 mg/day |
| Salawu et al.³⁸ | 30 years | 4 mg/day | Unknown | Sertraline | Sertraline | Risperidone |
| Owley et al.³⁹ | 17 years | 1.5 mg/day | 12 weeks | Lithium | No | Risperidone |
| Tekell et al.⁴⁰ | 41 years | 6 mg/day | 6 days | No | No | Unknown |
| Wang et al.⁴¹ | 37 years | 2 mg/day | 9 months | No | No | Clozapine 100 mg/day |
| Wang et al.⁴¹ | 27 years | Risperdal Consta 37.5 mg | 22 days | No | No | Clozapine 250 mg/day |
| Ginory and Nguyen⁴² | 50 years | 6 mg/day | 1 month | No | Trazodone | none |
| Unver et al.⁴³ | 12 years | 1 mg/day | 22 days | Methylphenidate | No | none |
| Aabbassi et al.⁴⁴ | 12 years | 2 mg/day | Few hours | No | No | Sulpiride 150 mg/day |
| Burk and Nelson⁹ | 34 years | Unknown | 2 years | Trazodone | Chlorpromazine, Trazodone, Quetiapine | Unknown |
| Baytunca et al.⁴⁵ | 13 years | 2.5 mg/day | 7 years | Methylphenidate | Quetiapine + Methylphenidate, Chlorpromazine | Quetiapine 25 mg/day |
| Şenormanci et al.⁴⁶ | 25 years | 4 mg/day | 2 years | No | No | Olanzapine 10 mg/day |
| Paklet et al.¹⁵ | 45 years | 4 mg/day | 3 days | Sodium valproate | No | Aripiprazole |
| Pradhan and Hardan⁰⁷ | 21 years | Between 0.5 and 3 mg/day | 9 years | No | No | none |
| Cruzado and Vallejos⁴⁸ | 32 years | 3 mg/day | 3 years | No | No | Risperidone 2 mg/day |
| Prabhushwamy et al.⁴⁹ | 12 years | 6 mg/day | 4 months | No | Olanzapine |
| Refai and Nakama⁵⁰ | 21 years | 6 mg/day | 4 days | No | No | Asenapine 10 mg/day |
| Eslami et al.⁵¹ | 35 years | 3 mg/day | 13 days | Clonazepam, Biperiden, Chlorpromazine | No | Unknown |
| Seger and Lamberti⁵² | 37 years | 6 mg/day | 3 months | Olanzapine + Fluvoxamine + Gabapentin + Oxazepam | No | Unknown |

Source: Adapted and updated from Paklet et al.¹⁵
and stable doses. In theory, polypharmacy may increase the risk of priapism, either through the synergy obtained by combining drugs that can independently induce this complication, or by combining drugs such as risperidone with another drug that affects the former’s metabolism. Some published cases have reported priapism following concomitant administration of risperidone and other molecules such as sertraline, lithium, fluvoxamine, valproate sodium and divalproex sodium, gabapentin, gabapentin, valproate sodium, lorazepam, oxazepam, oxaprozin, methylenidate, olanzapine, and so on.

However, it is not clear whether and to what extent the combination of different risk factors or the combination of several drugs increases the risk of priapism. Priapism could be considered an idiosyncratic reaction as it is not correlated with either the dosage of a psychotropic drug or the duration of its use. Furthermore, the lack of association between the dose and duration of antipsychotic treatment and the onset of priapism on the one hand and the other makes the phenomenon difficult to predict. It is therefore important to be aware of the risk of priapism, and to inform and monitor patients who may be susceptible to this side effect.

Based on the hypothesis that priapism is related to the blocking of α1-adrenergic receptors, we decided to substitute risperidone for olanzapine, a drug with low α1-adrenergic affinity, first orally, and then by extended-release injection. This switch was well tolerated by the patient: during the whole follow-up period (of more than 1 year), no further episode of priapism was observed. Donizete da Costa et al. also opted for a switch to olanzapine following an episode of priapism induced by clozapine. To our knowledge, no other medical team had chosen to introduce the extended-release injectable form of olanzapine following an episode of priapism.

In these different cases, the psychiatrists were faced with the challenge of treating the patient’s illness in light of the risk of priapism, which had been induced by different types of medication. This emphasizes the importance of considering pharmacodynamic properties of each drug while choosing the most appropriate medication for patients predisposed to this type of urological emergency. According to Aabbassi et al., if, after an episode of priapism, the patient needs to continue antipsychotic treatment, the dosage should be decreased, or the medication should be discontinued and replaced by another drug together with a medical follow-up, given the high risk of antipsychotic-induced priapism.

Most authors agree that when priapism is induced by an antipsychotic, it is recommended to switch to another molecule with fewer α1-blocking properties. In the published cases, most of the teams replaced risperidone with olanzapine, aripiprazole or clozapine. Few teams chose haloperidol, sulpiride, quetiapine, asenapine, fluphenazine or flupenthixol. To date, no consensus has been reached on the best choice of drug.

An alternative to antipsychotics could be the use of electroconvulsive therapy (ECT), which could be viable if psychotic symptoms are severe or disabling. Finally, to prevent the occurrence of priapism, some precautions should be taken. Any prescription of an antipsychotic treatment must be preceded by a careful interrogation centered on the patient’s sexual and andrological history in search of risk factors for priapism, such as episodes of prolonged erection, or previous episodes of priapism.

Conclusion

Priapism is a urological emergency requiring rapid treatment to avoid erectile sequelae. Priapism can be induced by antipsychotics, particularly those with a strong affinity to α-adrenergic receptors such as risperidone. Although rare, any patient on antipsychotics should be made aware of the possible occurrence of this side effect and the need to then seek urgent medical advice.

Overall, our study shows that the etiopathogenesis of this phenomenon is far from being fully understood. Further studies and research seem necessary to identify patients at higher risk of antipsychotic-induced priapism, and to propose clear alternative treatments should it occur.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent of the patient was taken before the case was submitted for publishing.
Author contributions

Sarra Ateb: Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing.

Taoufik Fourati: Methodology, Writing – review & editing.

Hammadi Ben Rejeb: Conceptualization, Writing – review & editing.

Dominique Januel: Conceptualization, Writing – review & editing.

Noomane Bouaziz: Conceptualization, Validation, Writing – review & editing.

Acknowledgements

None.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Competing Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Availability of data and materials

Not applicable.

ORCID iDs

Sarra Ateb https://orcid.org/0000-0002-8197-432X

Noomane Bouaziz https://orcid.org/0000-0003-1009-4891

References

1. Kovac JR, Mak SK, Garcia MM, et al. A pathophysiology-based approach to the management of early priapism. Asian J Androl 2013; 15: 20–26.

2. Burnett AL and Bivalacqua TJ. Priapism: current principles and practice. Urol Clin North Am 2007; 34: 631–642, viii.

3. Andersohn F, Schmedt N, Weinmann S, et al. Priapism associated with antipsychotics: role of α1 adrenoceptor affinity. J Clin Psychopharmacol 2010; 30: 68–71.

4. Abd El Salam MA and Foaad H. Chlorpromazine induced priapism from a single dose: an unusual complication of antipsychotic agent. Russ Open Med J 2017; 6: e0306.

5. Brichart N, Delavierre D, Peneau M, et al. Priapisme sous neuroleptiques. À propos de quatre patients. Prog Urol 2008; 18: 669–673.

6. Donizete da Costa F, Toledo da Silva Antoniali K and Dalgalarrondo P. Priapism and clozapine use in a patient with hypochondriacal delusional syndrome. Ox Med Case Reports 2015; 2015: 229–231.

7. Segreves RT. Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989; 46: 275–284.

8. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.

9. Burk BG and Nelson LA. Psychotropic-induced priapism in a treatment-refractory patient: a case report. J Pharm Pract 2021; 34: 309–313.

10. Sood S, James W and Bailon M-J. Priapism associated with atypical antipsychotic medications: a review. Int Clin Psychopharmacol 2008; 23: 9–17.

11. Doufik J, Otheman Y, Khalili L, et al. [Antipsychotic-induced priapism and management challenges: a case report]. Encephale 2014; 40: 518–521.

12. Saenz de Tejada I, Kim NN, Goldstein I, et al. Regulation of pre-synaptic alpha adrenergic activity in the corpus cavernosum. Int J Impot Res 2000; 12(Suppl. 1): S20–S25.

13. Bourgeois JA and Mundh H. Priapism associated with risperidone: a case report. J Clin Psychiatry 2003; 64: 15569.

14. Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol 2003; 170: 1318–1324.

15. Paklet L, Abe AM and Olajide D. Priapism associated with risperidone: a case report, literature review and review of the South London and Maudsley hospital patients’ database. Ther Adv Psychopharmacol 2013; 3: 3–13.

16. Sharma A and Fleisher MH. Risperidone-induced priapism: a case report. Prim Care Companion J Clin Psychiatry 2009; 11: 174–175.

17. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60(Suppl. 10): 5–14.
18. Makesar D and Thome J. Risperidone-induced priapism. *World J Biol Psychiatry* 2007; 8: 45–47.

19. Koirala S, Penagaluri P, Smith C, et al. Priapism and risperidone. *South Med J* 2009; 102: 1266–1268.

20. Ankem MK, Ferlise VJ, Han KR, et al. Risperidone-induced priapism. *Scand J Urol Nephrol* 2002; 36: 91–92.

21. Maizel S, Umansky L and Knobler HY. Risperidone-induced priapism. *Harefuah* 1996; 130: 744–745799.

22. Nicolson R and McCurley R. Risperidone-associated priapism. *J Clin Psychopharmacol* 1997; 17: 133–134.

23. du Toit RM, Millson RC, Heaton JP, et al. Priapism. *Can J Psychiatry* 2004; 49: 868–869.

24. Slauson SD and LoVecchio F. Risperidone-induced priapism with rechallenge. *J Emerg Med* 2004; 27: 88–89.

25. Haberfellner EM. Priapism with sertraline-risperidone combination. *Pharmacopsychiatry* 2007; 40: 44–45.

26. Madhusoodanan S, Brenner R, Gupta S, et al. Risperidone-associated priapism in an elderly man. *Am J Geriatr Psychiatry* 2002; 10: 355.

27. Kirshner A and Davis RR. Priapism associated with the switch from oral to injectable risperidone. *J Clin Psychopharmacol* 2006; 26: 626–628.

28. Emes CE and Millson RC. Risperidone-induced priapism. *Can J Psychiatry* 1994; 39: 315–316.

29. Sirota P and Bogdanov I. Priapism associated with risperidone treatment. *Int J Psychiatry Clin Pract* 2000; 4: 237–239.

30. Relan P, Gupta N and Mattoo SK. A case of risperidone-induced priapism. *J Clin Psychiatry* 2003; 64: 482–483.

31. Reeves RR and Mack JE. Priapism associated with two atypical antipsychotic agents. *Pharmacotherapy* 2002; 22: 1070–1073.

32. Penaskovic KM, Haq F and Raza S. Priapism during treatment with olanzapine, quetiapine, and risperidone in a patient with schizophrenia: a case report. *Prim Care Companion J Clin Psychiatry* 2010; 12: PCC.0900939.

33. Yang P and Tsai JH. Occurrence of priapism with risperidone-paroxetine combination in an autistic child. *J Child Adolesc Psychopharmacol* 2004; 14: 342–343.

34. Dodds PR, Dodds TJ and Mohr MA. A case of relapsing priapism associated with long-acting injectable risperidone. *Prim Care Companion CNS Disord* 2011; 13: PCC.1000995yel.

35. Lin Y-Y, Chu S-J and Tsai S-H. Association between priapism and concurrent use of risperidone and Ginkgo biloba. *Mayo Clin Proc* 2007; 82: 1289–1290.

36. Freudenreich O. Exacerbation of idiopathic priapism with risperidone-citalopram combination. *J Clin Psychiatry* 2002; 63: 249–250.

37. Rosenberg L, Aniskin D and Bernay L. Psychiatric treatment of patients predisposed to priapism induced by quetiapine, trazadone and risperidone: a case report. *Gen Hosp Psychiatry* 2009; 31: 98.

38. Salawu FK, Mustapha H and Danburam A. Priapism resulting from sertralinerisperidone combination in a 30-year-old Nigerian man with schizophrenia. *Ann Afr Med* 2010; 9: 195.

39. Owley T, Leventhal B and Cook EH Jr. Risperidone-induced prolonged erections following the addition of lithium. *J Child Adolesc Psychopharmacol* 2001; 11: 441–442.

40. Tekell JL, Smith EA and Silva JA. Prolonged erection associated with risperidone treatment. *Am J Psychiatry* 1995; 152: 1097.

41. Wang C-S, Kao W-T, Chen C-D, et al. Priapism associated with typical and atypical antipsychotic medications. *Int Clin Psychopharmacol* 2006; 21: 245–248.

42. Ginory A and Nguyen M. A case of priapism with risperidone. *Case Rep Psychiatry* 2014; 2014: 241573.

43. Unver H, Memik NC and Simsek E. Priapism associated with the addition of risperidone to methylphenidate monotherapy: a case report. *North Clin Istab* 2017; 4: 85–88.

44. Aabbassi B, Benali A and Asri F. Risperidone-induced priapism in an autistic child: a case report. *J Med Case Rep* 2016; 10: 164.

45. Baytunca MB, Kose S, Ozbaran B, et al. Risperidone, quetiapine and chlorpromazine may have induced priapism in a adolescent. *Pediatr Int* 2016; 58: 61–63.

46. Şenormanci Ö, Atasoy N, Konuk N, et al. Can priapism occur as an idiosyncratic reaction to risperidone? *Noro Psikiyatr Arş* 2016; 53: 186–187.

47. Pradhan T and Hardan A. Priapism associated with risperidone in a 21-year-old male with autism. *J Child Adolesc Psychopharmacol* 2013; 23: 367–368.
48. Cruzado L and Vallejos CE. [Priapism associated with risperidone use: report of one case]. *Rev Med Chil* 2012; 140: 1445–1448.

49. Prabhuswamy M, Srinath S, Girimaji S, *et al.* Risperidone-induced priapism in a 12-year-old boy with schizophrenia. *J Child Adolesc Psychopharmacol* 2007; 17: 539–540.

50. Refai S and Nakama HH. A case of priapism associated with rapid increase in risperidone dose. *Prim Care Companion CNS Disord* 2012; 14: PCC.12l01365.

51. Eslami Shahrbabaki M and Sabzevari L. Early onset priapism under chlorpromazine and risperidone therapy. *Iran J Psychiatry Behav Sci* 2011; 5: 139–142.

52. Seger A and Lamberti JS. Priapism associated with polypharmacy. *J Clin Psychiatry* 2001; 62: 128.

53. Birnbaum BF and Pinzone JJ. Sickle cell trait and priapism: a case report and review of the literature. *Cases J* 2008; 1: 429.

54. Torun F, Yılmaz E and Gümüş E. Priapism due to a single dose of quetiapine: a case report. *Turk Psikiyatri Derg* 2011; 22: 195–199.

55. Sinkeviciute I, Kroken RA and Johnsen E. Priapism in antipsychotic drug use: a rare but important side effect. *Case Rep Psychiatry* 2012; 2012: 496364.

56. Marrag I, Soussia RB, Hajji K, *et al.* Priapisme induit par la chlorpromazine: A propos de deux cas. *Afr J Urol* 2016; 22: 131–135.